WO2003060076A3 - Povidone-containing carriers for polypeptide growth factors - Google Patents

Povidone-containing carriers for polypeptide growth factors Download PDF

Info

Publication number
WO2003060076A3
WO2003060076A3 PCT/US2002/041077 US0241077W WO03060076A3 WO 2003060076 A3 WO2003060076 A3 WO 2003060076A3 US 0241077 W US0241077 W US 0241077W WO 03060076 A3 WO03060076 A3 WO 03060076A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factors
povidone
polypeptide growth
containing carriers
carriers
Prior art date
Application number
PCT/US2002/041077
Other languages
French (fr)
Other versions
WO2003060076A2 (en
Inventor
Rama Akella
John Ranieri
Original Assignee
Ct Pulse Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Pulse Biolog Inc filed Critical Ct Pulse Biolog Inc
Priority to JP2003560163A priority Critical patent/JP2005516971A/en
Priority to CA002470571A priority patent/CA2470571A1/en
Priority to EP02798571A priority patent/EP1465652A4/en
Priority to AU2002364100A priority patent/AU2002364100B2/en
Publication of WO2003060076A2 publication Critical patent/WO2003060076A2/en
Publication of WO2003060076A3 publication Critical patent/WO2003060076A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

A liquid carrier medium is provided which is suitable for solubilizing growth factors, such as mixtures of bone morphogenetic proteins, that are found to induce an angiogenic response in ischemic tissues. The liquid medium comprises an aqueous solution of polyvinyl pyrrolidone.
PCT/US2002/041077 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors WO2003060076A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003560163A JP2005516971A (en) 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors
CA002470571A CA2470571A1 (en) 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors
EP02798571A EP1465652A4 (en) 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors
AU2002364100A AU2002364100B2 (en) 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/027,669 2001-12-21
US10/027,669 US6992066B2 (en) 1998-10-16 2001-12-21 Povidone-containing carriers for polypeptide growth factors

Publications (2)

Publication Number Publication Date
WO2003060076A2 WO2003060076A2 (en) 2003-07-24
WO2003060076A3 true WO2003060076A3 (en) 2004-03-04

Family

ID=21839103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041077 WO2003060076A2 (en) 2001-12-21 2002-12-23 Povidone-containing carriers for polypeptide growth factors

Country Status (6)

Country Link
US (3) US6992066B2 (en)
EP (1) EP1465652A4 (en)
JP (1) JP2005516971A (en)
AU (1) AU2002364100B2 (en)
CA (1) CA2470571A1 (en)
WO (1) WO2003060076A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) * 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7241874B2 (en) * 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7074412B2 (en) * 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
FR2948286B1 (en) * 2009-07-27 2011-08-26 Jean-Noel Thorel INJECTABLE COMPOSITION COMPRISING A FILLING AGENT AND A FIBROBLAST GROWTH MEDIUM
EP2537538A1 (en) * 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing
WO2014142805A1 (en) 2013-03-12 2014-09-18 PEARISO, Christopher System and methods for facilitating the development and management of creative assets
WO2015093924A1 (en) * 2013-12-19 2015-06-25 CASTRO ALDRETE, Jorge Issac Vehicle for the administration of pharmaceutical compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927205A (en) * 1973-04-09 1975-12-16 Takeda Chemical Industries Ltd Aqueous suspension of pharmaceuticals
EP0516901A1 (en) * 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
CN1163780A (en) * 1997-04-17 1997-11-05 中国人民解放军第四军医大学全军创伤骨科研究所 Osteogenesis stimulin injection and its preparing process
US20020009789A1 (en) * 2000-03-21 2002-01-24 Jcr Pharmaceuticals Co., Ltd. Powder containing physiologically active peptide

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656587A (en) 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5705477A (en) 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
US5328695A (en) 1983-03-22 1994-07-12 Massachusetts Institute Of Technology Muscle morphogenic protein and use thereof
US4699788A (en) 1984-08-20 1987-10-13 Trustees Of Boston University Angiogenic factor methods of extraction and method for producing angiogenesis
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US4902296A (en) * 1986-10-29 1990-02-20 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
US4743259A (en) * 1986-10-29 1988-05-10 The University Of Virginia Alumni Patents Foundation Use of demineralized bone matrix in the repair of segmental defects
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US4863732A (en) * 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US4895838A (en) 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US4900673A (en) 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
US5256644A (en) * 1988-05-20 1993-10-26 Institute Of Molecular Biology, Inc. Wound healing using IGF-II and TGF
US5219576A (en) 1988-06-30 1993-06-15 Collagen Corporation Collagen wound healing matrices and process for their production
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5073373A (en) * 1989-09-21 1991-12-17 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5290558A (en) * 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
EP0513334A4 (en) * 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
ATE164167T1 (en) 1990-12-21 1998-04-15 Curative Tech Inc ANGIOGENIC PEPTIDES
US5972884A (en) 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5290763A (en) 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
WO1993000432A1 (en) 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
DE4121043A1 (en) * 1991-06-26 1993-01-07 Merck Patent Gmbh BONE REPLACEMENT MATERIAL WITH FGF
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
AU674500B2 (en) 1991-11-04 1997-01-02 Genetics Institute, Llc Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6120760A (en) 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
US5318957A (en) 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
US5830859A (en) * 1992-09-17 1998-11-03 Schmidt; Karlheinz Complex for inducing bone growth in the maxillary sinus
US5616490A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US5516532A (en) * 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US5677276A (en) 1994-12-23 1997-10-14 La Jolla Cancer Research Foundation Immobilization of peptides to hyaluronate
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
CA2224253A1 (en) 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US7026292B1 (en) * 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
PT876165E (en) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE
US6322786B1 (en) * 1996-02-15 2001-11-27 Kansas University Medical Center Research Institute, Inc. Method of producing bone-inducing agent
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US20010007023A1 (en) * 1997-08-13 2001-07-05 John W. Lough Jr. Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
US6189537B1 (en) * 1996-09-06 2001-02-20 Lifenet Process for producing osteoinductive bone, and osteoinductive bone produced thereby
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US5928940A (en) 1996-09-24 1999-07-27 Creative Biomolecules, Inc. Morphogen-responsive signal transducer and methods of use thereof
US6679918B1 (en) * 1997-02-13 2004-01-20 Centerpulse Biologics Inc. Implantable putty material
GB9714276D0 (en) 1997-07-08 1997-09-10 Univ Dundee Peptides and related compounds
JP2002508173A (en) 1997-12-17 2002-03-19 クリエイティブ バイオモレキュールズ， インコーポレイテッド A method for maintaining or restoring a phenotype appropriate for a tissue of soft tissue cells.
US20050096274A1 (en) * 1998-04-07 2005-05-05 Lough John W. Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
US6211157B1 (en) * 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
AU6411199A (en) * 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
JP2000224062A (en) * 1999-02-01 2000-08-11 Sony Corp Digital audio broadcast receiver
EP1171155A2 (en) 1999-04-23 2002-01-16 Research Corporation Technologies Therapeutic compositions and methods for enhancing angiogenesis
DE19925519A1 (en) * 1999-06-04 2000-12-07 Lohmann Therapie Syst Lts Laminar wound dressing for controlled release of active substance e.g. platelet derived growth factor, includes layer containing polymer and hydrogel as fluid absorber
AU782394B2 (en) * 1999-06-29 2005-07-21 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
AU6634400A (en) * 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
US6541447B1 (en) * 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
US6534095B1 (en) * 1999-09-03 2003-03-18 Lifenet Pulsatile acidification wave demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby
AU2001236632A1 (en) * 2000-02-03 2001-08-14 Regeneration Technologies, Inc. Extraction of growth factors from tissue
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US6930089B2 (en) * 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US20030104977A1 (en) 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7081240B1 (en) 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
US20020025340A1 (en) * 2000-08-30 2002-02-28 Dyer Wallace K. Methods and compositions for tissue augmentation
US20050064041A1 (en) * 2000-09-05 2005-03-24 Lifenet Continuous acidification demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby
US20020173453A1 (en) 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US6492327B2 (en) * 2000-12-19 2002-12-10 Sulzer Biologics Inc. Isolation of purified TGF- β1 and TGF -β2 from bone tissue
DE60230873D1 (en) * 2001-04-25 2009-03-05 Eidgenoess Tech Hochschule MEDICAMENT RELEASING MATRICES FOR THE PROMOTION OF WOUND HEALING
US7241446B2 (en) * 2002-04-01 2007-07-10 Trustees Of Dartmouth College Methods for modulating angiogenesis via VEGF
US7241874B2 (en) * 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US20070066525A1 (en) * 2004-02-04 2007-03-22 Lee John C Compositions and therapeutic methods using morphogenic proteins
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US20070014869A1 (en) * 2005-07-15 2007-01-18 Cormatrix Cardiovascular, Inc. Compositions for reconstruction, replacement or repair of intracardiac tissue
US8568761B2 (en) * 2005-07-15 2013-10-29 Cormatrix Cardiovascular, Inc. Compositions for regenerating defective or absent myocardium

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927205A (en) * 1973-04-09 1975-12-16 Takeda Chemical Industries Ltd Aqueous suspension of pharmaceuticals
EP0516901A1 (en) * 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution
US5543392A (en) * 1992-07-29 1996-08-06 Morinaga Milk Industry Co., Ltd. Digestive tract cell activating agent of EGF and lactoferrin
CN1163780A (en) * 1997-04-17 1997-11-05 中国人民解放军第四军医大学全军创伤骨科研究所 Osteogenesis stimulin injection and its preparing process
US20020009789A1 (en) * 2000-03-21 2002-01-24 Jcr Pharmaceuticals Co., Ltd. Powder containing physiologically active peptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 132, no. 4, 24 January 2000, Columbus, Ohio, US; abstract no. 40522X, HU ET AL.: "Injection of basic fibroblast growth factor and bone morphogenetic protein for osteogenesis stimulation" page 1132; XP002965981 *
MUELLER ET AL.: "Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment)", SWISS MEDICAL WEEKLY, vol. 131, 12 January 2001 (2001-01-12), pages 23 - 25, XP002965980 *
PROCHAZKA ET AL.: "Epidermal growth factor and insulin growth factor 1 increase FSH-stimulated expansion of porcine cumulus cells in sperum-free medium", JOURNAL OF REPRODUCTION AND FERTILITY, no. 25, July 2000 (2000-07-01), pages 64, ABSTRACT 173, XP008102509 *
See also references of EP1465652A4 *

Also Published As

Publication number Publication date
JP2005516971A (en) 2005-06-09
AU2002364100A1 (en) 2003-07-30
US7341999B2 (en) 2008-03-11
US20060128625A1 (en) 2006-06-15
AU2002364100B2 (en) 2008-07-17
EP1465652A2 (en) 2004-10-13
CA2470571A1 (en) 2003-07-24
US6992066B2 (en) 2006-01-31
US20080113916A1 (en) 2008-05-15
EP1465652A4 (en) 2009-06-17
WO2003060076A2 (en) 2003-07-24
US20030022828A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
AU2180700A (en) Antisense modulation of novel anti-apoptotic bcl-2-related proteins
AU2002348283A1 (en) Additive solution for blood preservation
WO2002030463A3 (en) Reduced-viscosity concentrated protein formulations
AU6726496A (en) Two-pulse, lateral tissue illuminator
AU2001276344A1 (en) System for removing body fluid, especially blood
ZA979820B (en) Methods for draping surgical incision sites.
WO2003060076A3 (en) Povidone-containing carriers for polypeptide growth factors
AU2001285751A1 (en) Liquid collagen hemostat
EP1967590A3 (en) Lentiviral packaging constructs
AU7692598A (en) Active phase splitter
EP0826966A3 (en) Method for stabilizing platelets
HK1049432A1 (en) Transparent high oil loaded microemulsions
AU2002343356A1 (en) Antisense modulation of protein kinase r expression
AU2001253297A1 (en) Sterilization process for air, liquid and surfaces
AU3425700A (en) Non-ribosomal peptide synthetases, method for producing same and the use thereof
MXPA01003868A (en) Apomixis conferred by expression of serk interacting proteins.
AU2001232238A1 (en) Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredient
AU2001274536A1 (en) Insulin-like growth factor-binding protein
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
AU2001259195A1 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
AU2001293948A1 (en) Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator
ATE288909T1 (en) INDOLE DERIVATIVES USABLE FOR THE TREATMENT OF, AMONG OTHERS. OSTEOPOROSIS
EP1262195A4 (en) Vasoactive agents
AU4073600A (en) Bone morphogenic proteins
AU2001256585A1 (en) Method for constructing, representing or displaying protein interaction maps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2470571

Country of ref document: CA

Ref document number: 2002364100

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003560163

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002798571

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002798571

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002364100

Country of ref document: AU

Date of ref document: 20021223

Kind code of ref document: B